Skip to content

Category: Diseases

Choroideremia Gene Therapy Moves into Phase 3 Human Study

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Choroideremia Gene Therapy Moves into Phase 3 Human Study Audio version: Nightstar Therapeutics, a retinal-disease, gene-therapy development company in the UK, is advancing its emerging gene therapy for choroideremia into a Phase 3 clinical trial known as STAR.…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A

Source: Foundation Fighting Blindness Blog – Eye on the Cure – FFB-CRI Investing .5 Million in Emerging Therapy for USH2A Audio version: The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.

Source: Foundation Fighting Blindness Blog – Eye on the Cure – AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S. Audio version:Applied Genetic Technologies Corporation (AGTC) is now recruiting for its Phase 1/2 gene therapy clinical trial for males with X-linked retinitis pigmentosa (XLRP) caused by…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease Audio Version:Your browser does not support the audio element. Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest